Communicable disease threats report, 8-14 July 2018, week 28
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 July 2018 and includes updates on carbapenemase-producing (OXA-48) Klebsiella pneumoniae, dengue, Ebola virus disease, poliomyelitis, MERS-CoV, mass gathering monitoring (FIFA Men's Football World Cup), measles, poliovirus type 2, rubella, Vibrio growth in the Baltic Sea, and West Nile virus.
ECDC study protocol for genomic-based surveillance of carbapenem-resistant and/or colistin-resistant Enterobacteriaceae at the EU level
This ECDC study protocol describes the technical requirements for implementing future EU-level genomic-based surveillance of carbapenem-resistant and/or colistin-resistant Enterobacteriaceae.
Cross-border transfer increases patients’ risk of resistant bacteriaArchived
Patient transfer between hospitals and in particular between countries, is a risk factor for the spread of bacteria that are resistant to last-line antibiotics. More specifically, for highly resistant bacteria, like carbapenamase-producing Enterobacteriaceae (CPE), the risk is heightened when patients are transferred from, or have received previous medical care in areas with high rates of bacterial resistance. These are conclusions from a risk assessment produced by ECDC that evaluated the risk to the citizens of Europe, of the spread of CPE through patient transfer between healthcare facilities, with special emphasis on cross-border transfer.
US CDC guidance for control of carbapenem-resistant Enterobacteriaceae (CRE) – 2012 CRE toolkitArchived
Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae (CPE) are highly resistant to antibiotics, leaving only a few options for treatment of infected patients, and thus represent a serious threat to public health.
US CDC report on antibiotic resistance threats in the United States, 2013
Antimicrobial resistance represent a serious threat to public health and patient safety and is a worldwide problem. Each year, in the European Union (EU) at least 25 000 patients die of infections with multidrug-resistant bacteria.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, 14 April 2016
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
ECDC country visit to Norway to discuss antimicrobial resistance issues
An ECDC country visit team conducted an assessment mission during the period 12–16 March 2018 to discuss antimicrobial resistance (AMR) issues in Norway. The overall objective of the mission was to provide an observation-based assessment of the situation in Norway regarding prevention and control of AMR through prudent use of antibiotics and infection control.
New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: Emergence and response in Europe
Struelens, M.J., Monnet, D.L., Magiorakos, A.P., O'Connor, F.S., Giesecke, J.
Antimicrobial resistance 2010: Global attention on carbapenemase-producing bacteria
Monnet, D.L., Suetens, C., Earnshaw, S., Gagliotti, C., Griskeviciene, J., Heuer, O.E., Khazeeva, E., Kleinkauf, N., Liljestedt, E., Magiorakos, A.-P., Santos, F., Struelens, M.J., Weber, J.T., Weist, K.